A Phase 3 interventional study of CagriSema and Semaglutide in Hypertension and Obesity, sponsored by Novo Nordisk A/S. Not yet recruiting at 212 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,031 studies in Hypertension with a site in United States, this one is the 115th largest by planned enrollment of the 1,779 interventional ones that give a count, is one of 101 that started in 2026, is one of 202 in phase 3, reaches primary completion later than 262 of the 367 other live ones, and was the 2,029th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,031 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 101 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,408 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,779 interventional studies, 200 across the 238 observational. Of the 1,514 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,031 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
143 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 143 to your calendar (.ics) → With an account.
Among the 2,031 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants with Type 2 Diabetes (T2D)
The following inclusion criteria apply at screening in addition to the inclusion criteria listed above:
Exclusion Criteria:
For participants without T2D
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive CagriSema subcutaneously once weekly.
Drug: CagriSema
Participants will receive semaglutide subcutaneously once weekly.
Drug: Semaglutide
Participants will receive cagrilintide subcutaneously once weekly.
Drug: Cagrilintide
Participants will receive placebo subcutaneously once weekly.
Drug: Placebo
CagriSema will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Cagrilintide will be administered subcutaneously.
Placebo will be administered subcutaneously.
CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP)
Measured in millimeters of mercury (mmHg).
Time frame: From baseline (week 0) to week 32
CagriSema versus Semaglutide and Cagrilintide : Change in in-office systolic blood pressure
Measured in mmHg.
Time frame: From baseline (week 0) to week 32
Change in Home blood pressure monitoring (HBPM) -based systolic blood pressure
Measured in mmHg.
Time frame: From baseline (week 0) to week 32
Number of participants who achieve a target goal of in-office systolic blood pressure lesser than or equal to (≤) 130 mmHg
Measured as Count of participants.
Time frame: At Week 32
Number of participants who achieve American College of Cardiology and the American Heart Association (ACC/AHA) guidelines based blood pressure targets lesser than (<) 130/80 mmHg
Measured as Count of participants.
Time frame: At Week 32
Change in body weight (%)
Measured in percentage (%).
Time frame: From baseline (week 0) to week 32
Change in body weight (Kg)
Measured in Kilograms (kg).
Time frame: From baseline (week 0) to week 32
Change in waist circumference
Measured in centimetre (cm).
Time frame: From baseline (week 0) to week 32
Change in ACC/AHA 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
Measured in percentage of risk. ACC/AHA risk estimator calculates 10 year risk of ASCVD using a formula which includes age, sex, race, total cholesterol, high density lipoprotein (HDL) cholesterol, systolic blood pressure, blood pressure medication use, diabetes status, smoking status; minimum score 0, maximum score 100 where higher score indicates higher risk of 10-year risk of ASCVD.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Total cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: HDL cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Low Density Lipoprotein (LDL) cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Very Low Density Lipoprotein (VLDL) cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Non-HDL cholesterol
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of lipids: Triglycerides
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Ratio to baseline of high-sensitivity C-reactive protein (hsCRP)
Measured in Ratio.
Time frame: From baseline (week 0) to week 32
Showing the first 100 of 212 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2028, 18 months later.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 18 months is close to that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide